Key result
SGLT2 inhibitors show no association with dementia or Parkinson's disease risk versus controls.
Why the study?
The potential effects of SGLT2i therapy on the risks of dementia and Parkinson's disease are not well established, with conflicting results from observational studies.
Does SGLT2i therapy affect the risk of dementia and Parkinson's disease in patients with type 2 diabetes mellitus, heart failure, or chronic kidney disease?
Population
74,442 patients with type 2 diabetes mellitus, heart failure, or chronic kidney disease across 12 RCTs
Comparison
SGLT2i vs control
Design
Meta-analysis of 12 randomized controlled trials
Authors
Loading...
SGLT2i show no increased dementia or Parkinson's risk; challenges conflicting observational data and supports neurocognitive safety in T2DM and HF.
Meta-Analysis (n=74,442)
Does SGLT2i therapy affect the risk of dementia and Parkinson's disease in patients with type 2 diabetes mellitus, heart failure, or chronic kidney disease?
Odds Ratio: 1.37 (95% CI 0.7–2.69)
p-value: p=.36
This meta-analysis demonstrates that SGLT2 inhibitors do not significantly increase or decrease the risk of incident dementia or Parkinson's disease.
Jaiswal et al. (2024) conducted a meta-analysis in type 2 diabetes mellitus, heart failure, or chronic kidney disease (n=74,442). SGLT2 inhibitors vs. control was evaluated on risk of dementia (OR 1.37, 95% CI 0.70-2.69, p=.36). SGLT2 inhibitors were not significantly associated with the risk of dementia (OR 1.37; 95% CI 0.70-2.69; P=.36) or Parkinson's disease (OR 0.63; 95% CI 0.25-1.61; P=.33) compared with controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: